P.O. Box 30192
Salt Lake City, UT 84120-0192
801-442-4912 or 800-442-3219
Fax 801-442-3006

selecthealth℠

PREAUTHORIZATION FORM

Nexavar™
(sorafenib)

Therapeutic use: Multikinase inhibitor used in the treatment of advanced renal cell carcinoma and hepatocellular carcinoma.

Quantity Limit: 800 mg daily (2 X 200 mg tablets twice daily)

Authorization Period: 12 months

Patient's name _____

Patient's ID# | | | | | | | | | | DOB | | | / | | | / | | | | |

ICD-9 | | | | | | | | | | | | _____

Physician's name_____

Physician's Ph# (| | |) | | | | - | | | | | Fax# | | | | - | | | | |

Physician's signature_____ Date signed | | | / | | | / | | | | |

Supervising Physician's name_____ (Required if requesting provider is a nurse practitioner or physician assistant)

Please check "Yes" or "No" and respond to the following requests:			
1.	Does the patient have advanced renal cell carcinoma?	❑ Yes	❑ No
2.	Does the patient have advanced hepatocellular carcinoma (HCC)?	❑ Yes	❑ No
2a.	If Nexavar is being used for HCC, is the patient being treated for an unresectable tumor or recurrent disease?	❑ Yes	❑ No
3.	Is Nexavar being used as monotherapy? (Not covered in combination with other chemotherapies)	❑ Yes	❑ No

This form is intended for SelectHealth members only. All requests for preauthorization should be sent via fax to 1-801-442-3006. Missing, inaccurate, or incomplete information may cause a delay or denial of authorization.

© 2010 SelectHealth. All rights reserved. 1306 02/10
Last Updated: February 23, 2010